Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14861352 | 1.00 | PPM1D (0.32) | PPM1D | |
| SCHEMBL16554702 | 1.00 | PPM1D (0.32) | PPM1D | |
| SCHEMBL15594486 | 0.79 | — | — | |
| SCHEMBL15979224 | 0.79 | — | — | |
| SCHEMBL1564530 | 0.77 | PPM1D (0.30) | PPM1D | |
| SCHEMBL1564528 | 0.77 | PPM1D (0.30) | PPM1D | |
| SCHEMBL1564533 | 0.77 | PPM1D (0.30) | PPM1D | |
| SCHEMBL14863775 | 0.76 | — | — | |
| SCHEMBL14358050 | 0.76 | — | — | |
| SCHEMBL15032469 | 0.75 | CA2 (0.33) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110312706-B | Indanyl aminopyridyl cyclopropanecarboxylic acid, pharmaceutical composition and application thereof | 勃林格殷格翰国际有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-110214135-B | Indanyl amino pyrazinyl cyclopropane carboxylic acid, pharmaceutical composition and application thereof | 勃林格殷格翰国际有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-3573965-B1 | INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3544958-B1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-10253004-B2 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-04-09 | — | — | US | disclosed |
| US-10125101-B2 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-13 | — | — | US | disclosed |
| US-10093660-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATONAL GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-3077383-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-3077383-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | Evotec International GmbH (DE) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082324-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253004-B2 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR55, GPR65 | PPM1D 3712/4885 |
| US-10125101-B2 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR55 | PPM1D 3516/4885 |
| US-20180208560-A1 | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR55, GPR65 | PPM1D 3712/4885 |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, NEK2, SIK2 | PPM1D 2166/4885 |
| US-20180148411-A1 | INDANYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GPR119, GPR65, GPR55 | PPM1D 3516/4885 |
| US-10093660-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | NEK5, NEK2, SIK2 | PPM1D 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.